Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model

Journal of Virology

Volumn 84, Issue 18, 2010, Pages 9427-9438

  Hurt, Aeron C ^a,b   Nor'e, Siti Sarah ^a,b   McCaw, James M ^c   Fryer, Helen R ^d   Mosse, Jennifer ^b   McLean, Angela R ^d   Barr, Ian G ^a,b  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b UNIVERSITY OF BALLARAT   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRUS PROTEIN; VIRUS RNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DONOR; EXPERIMENTAL MODEL; FERRET; GENETIC ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS; INFLUENZA VIRUS A H3N2; MATHEMATICAL MODEL; MIXED INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; WILD TYPE; ANIMAL; ANTIVIRAL RESISTANCE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MOLECULAR GENETICS; PHYSIOLOGY; THEORETICAL MODEL; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FERRETS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MODELS, THEORETICAL; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 77956045410     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00373-10     Document Type: Article

References (36)

1. Asquith, B., C. T. Edwards, M. Lipsitch, and A. R. McLean. 2006. Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol. 4:e90.
2. Bouvier, N. M., A. C. Lowen, and P. Palese. 2008. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J. Virol. 82:10052-10058.
3. Collins, P. J., L. F. Haire, Y. P. Lin, J. Liu, R. J. Russell, P. A. Walker, J. J. Skehel, S. R. Martin, A. J. Hay, and S. J. Gamblin. 2008. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258-1261.
4. Dharan, N. J., L. V. Gubareva, J. J. Meyer, M. Okomo-Adhiambo, R. C. McClinton, S. A. Marshall, K. St. George, S. Epperson, L. Brammer, A. I. Klimov, J. S. Bresee, and A. M. Fry. 2009. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041.
5. Gerloff, N. A., J. R. Kremer, J. Mossong, M. Opp, and C. P. Muller. 2009. Genomic diversity of oseltamivir-resistant influenza virus A (H1N1), Luxembourg, 2007-08. Emerg. Infect. Dis. 15:1523-1524.
6. Gubareva, L. V., M. N. Matrosovich, M. K. Brenner, R. C. Bethell, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
7. Gubareva, L. V., M. J. Robinson, R. C. Bethell, and R. G. Webster. 1997. Catalytic and framework mutations in the neuraminidase active site of in- fluenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71: 3385-3390.
8. Gulland, A. 2009. First cases of spread of oseltamivir resistant swine flu between patients are reported in Wales. BMJ 339:b4975.
9. Herlocher, M. L., J. Carr, J. Ives, S. Elias, R. Truscon, N. Roberts, and A. S. Monto. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111.
10. Herlocher, M. L., R. Truscon, S. Elias, H. L. Yen, N. A. Roberts, S. E. Ohmit, and A. S. Monto. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
11. Hurt, A. C., J. Ernest, Y. Deng, P. Iannello, T. G. Besselaar, C. Birch, P. Buchy, M. Chittaganpitch, S. C. Chiu, D. E. Dwyer, A. Guigon, B. Harrower, I. P. Kei, T. Kok, C. Lin, K. McPhie, A. Mohd, R. Olveda, T. Panayotou, W. Rawlinson, L. Scott, D. Smith, H. D'Souza, N. Komadina, R. Shaw, A. Kelso, and I. G. Barr. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
12. Hurt, A. C., H. T. Ho, and I. Barr. 2006. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev. Anti Infect. Ther. 4:795-805.
13. Ives, J. A. L., J. A. Carr, D. B. Mendel, C. Y. Tai, R. Lambkin, L. Kelly, J. S. Oxford, F. G. Hayden, and N. A. Roberts. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo. Antiviral Res. 55:307-317.
14. Jackson, H. C., N. Roberts, Z. M. Wang, and R. Belshe. 2000. Management of influenza: use of new antivirals and resistance in perspective. Clin. Drug Invest. 20:447-454.
15. Jackson, S., H. N. Van, L. M. Chen, T. R. Maines, N. J. Cox, J. M. Katz, and R. O. Donis. 2009. Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. J. Virol. 83:8131-8140.
16. Kiso, M., K. Mitamura, Y. Sakai-Tagawa, K. Shiraishi, C. Kawakami, K. Kimura, F. G. Hayden, N. Sugaya, and Y. Kawaoka. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765. (Pubitemid 39165094)
17. Le, Q. M., H. F. Wertheim, N. D. Tran, H. R. van Doorn, T. H. Nguyen, and P. Horby. 2010. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N. Engl. J. Med. 362:86-87.
18. Lipsitch, M., T. Cohen, M. Murray, and B. R. Levin. 2007. Antiviral resistance and the control of pandemic influenza. PLoS Med. 4:e15.
19. Matrosovich, M., T. Matrosovich, J. Carr, N. A. Roberts, and H. D. Klenk. 2003. Overexpression of the α-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425.
20. McCaw, J. M., J. G. Wood, E. S. McBryde, T. M. Nolan, J. T. Wu, M. Lipsitch, and J. McVernon. 2009. Understanding Australia's influenza pandemic policy on the strategic use of the antiviral drug stockpile. Med. J. Aust. 191:136-137.
21. McCaw, J. M., J. G. Wood, C. T. McCaw, and J. McVernon. 2008. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS One 3:e2362.
22. McKimm-Breschkin, J. L. 2000. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. 47:1-17. (Pubitemid 30621392)
23. McVernon, J., J. M. McCaw, and T. M. Nolan. 2010. Modelling strategic use of the national stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response. Aust. N. Z. J. Public Health 34:113-119.
24. Meijer, A., A. Lackenby, O. Hungnes, B. Lina, S. van der Werf, B. Schweiger, M. Opp, J. Paget, J. van de Kassteele, A. Hay, and M. Zambon. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
25. Perez, D. R., E. Sorrell, M. Angel, J. Ye, D. Hickman, L. Pena, G. Ramirez-Nieto, B. Kimble, and Y. Araya. 2009. Fitness of pandemic H1N1 and seasonal influenza A viruses during co-infection: evidence of competitive advantage of pandemic H1N1 influenza versus seasonal influenza. PLoS Curr. Influenza August:RRN1011.
26. Rameix-Welti, M. A., V. Enouf, F. Cuvelier, P. Jeannin, and S. van der Werf. 2008. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4:e1000103.
27. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
28. Smith, H., and C. Sweet. 1988. Lessons for human influenza from pathogenicity studies with ferrets. Rev. Infect. Dis. 10:56-75.
29. Staschke, K. A., J. M. Colacino, A. J. Baxter, G. M. Air, A. Bansal, W. J. Hornback, J. E. Munroe, and W. G. Laver. 1995. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214:642-646.
30. Tai, C. Y., P. A. Escarpe, R. W. Sidwell, M. A. Williams, W. Lew, H. Wu, C. U. Kim, and D. B. Mendel. 1998. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42:3234-3241.
31. Tannock, G. A., J. A. Paul, R. Herd, R. D. Barry, A. L. Reid, M. J. Hensley, R. S. Gillett, S. M. Gillett, P. Lawrance, and R. L. Henry. 1989. Improved colorimetric assay for detecting influenza B virus neutralizing antibody responses to vaccination and infection. J. Clin. Microbiol. 27:524-528.
32. Wang, M. Z., C. Y. Tai, and D. B. Mendel. 2002. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46:3809-3816.
33. Whitley, R. J., F. G. Hayden, K. S. Reisinger, N. Young, R. Dutkowski, D. Ipe, R. G. Mills, and P. Ward. 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-133.
34. WHO. Accessed 20 November 2009. Pandemic (H1N1) 2009 - update. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/ swineflu/laboratory20-11-2009/en/index.html.
35. Wu, J. T., G. M. Leung, M. Lipsitch, B. S. Cooper, and S. Riley. 2009. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med. 6:e1000085.
36. Yen, H. L., L. M. Herlocher, E. Hoffmann, M. N. Matrosovich, A. S. Monto, R. G. Webster, and E. A. Govorkova. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49:4075-4084.